Biosimilars | Current Treatment | Oncology | US/EU | 2020
In 2019, Amgen / Allergan’s trastuzumab biosimilar Kanjinti and bevacizumab biosimilar Mvasi were the first monoclonal antibody (MAb) biosimilars launched in the United States, followed by Celltrion / Teva’s Truxima (rituximab biosimilar), Biocon / Mylan’s Ogivri (trastuzumab biosimilar), and Pfizer’s Zirabev (bevacizumab biosimilar). Several different MAb biosimilars have appeared since on the U.S. market including the rituximab biosimilar Ruxience and the trastuzumab biosimilars Trazimera, Herzuma, and Ontruzant. Following the launch of the rituxumab biosimilars in Europe in 2017, several trastuzumab and bevacizumab biosimilars have furhter expanded the biosimilars sector of the European oncology market. Uptake of these MAb biosimilars and granulocyte colony-stimulating factor (G-CSF) and erythropoiesis-stimulating agent (ESA) biosimilars will depend on oncologists’ prescribing behavior. To help manufacturers / marketers of oncology biosimilars and brands understand the opinions, actions, and expectations of these physicians, Decision Resources Group has conducted new primary market research with oncologists in France, Germany, and the United States on the use of branded drugs versus their biosimilar competitors.
Questions answered:
What is the current patient share of oncology biosimilars, and what expectations do oncologists have for future patient shares, assuming additional biosimilars launch?
How similar do oncologists believe biosimilars are to their reference brands?
What factors do oncologists identify as being the key drivers and barriers to biosimilar uptake?
What percentage of biosimilar-treated patients were initiated on a biosimilar, and what percentage were switched from a reference brand?
What cost reduction is required for a biosimilar to achieve more than a 50% patient share?